Oculus Innovative Sciences Announces Closing of Public Offering of 8,625,000
Shares of Common Stock
PETALUMA, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs,
produces and markets innovative, safe and effective drugs, devices and
nutritional products, today announced the closing of its underwritten public
offering of 8,625,000 shares of common stock at an offering price of $0.40 per
share, including 1,125,000 shares of its common stock to cover the
over-allotment. Oculus received gross proceeds of $3.45 million.
Oculus intends to use the net proceeds from this offering for the repayment of
debt and for general corporate purposes. In connection with the repayment of
debt, Oculus intends to retire a portion of the common stock previously issued
to its lenders.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
Dawson James Securities, Inc. acted as a co-manager for the offering.
A shelf registration statement and accompanying base prospectus on Form S-3
relating to the shares was filed with the Securities and Exchange Commission
and is effective. Copies of the final prospectus supplement relating to the
offering may be obtained from the offices of Aegis Capital Corp., Prospectus
Department, 810 Seventh Avenue, 18^th Floor, New York, NY, 10019, telephone:
212-813-1010 or email: firstname.lastname@example.org, or from the SEC's website at
This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial healthcare
company that designs, produces and markets innovative, safe and effective
drugs, devices and nutritional products. Oculus is pioneering innovative
solutions in multiple markets for the dermatology, surgical, wound care and
animal healthcare markets, and has commercialized products in the United
States, Europe, India, China, Mexico and select Middle East countries. The
company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.
Except for historical information herein, matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of
words such as "intends," and "cover," among others. Forward-looking statements
in this press release are subject to certain risks and uncertainties inherent
in the Company's business that could cause actual results to vary, including
such risks that regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards or receipt
of required regulatory clearances or approvals, clinical results may not be
replicated in actual patient settings, protection offered by the Company's
patents and patent applications may be challenged, invalidated or circumvented
by its competitors, the available market for the Company's products will not
be as large as expected, the Company's products will not be able to penetrate
one or more targeted markets, revenues will not be sufficient to fund further
development and clinical studies, the Company may not meet its future capital
needs, and its ability to obtain additional funding, as well as uncertainties
relative to varying product formulations and a multitude of diverse regulatory
and marketing requirements in different countries and municipalities, and
other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission including the Company's annual report on
Form 10-K for the year ended March 31, 2012. Oculus Innovative Sciences
disclaims any obligation to update these forward-looking statements except as
required by law.
Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.
CONTACT: Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Press spacebar to pause and continue. Press esc to stop.